Mindray Bio-Medical Electronics

Explore the latest insights on Mindray Bio-Medical Electronics and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Mindray Bio-Medical Electronics’ developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Company Drug

Biokin Scores Triple NMPA Breakthrough Therapy Designation – BL-M07D1, BL-M05D1, and Iza‑Bren Recognized Across Biliary Tract and Gastric Cancers

Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its three drug candidates – BL-M07D1, BL-M05D1, and izalontamab bretecan – have been granted Breakthrough Therapy Designation (BTD) by the Center…

September 28, 2026

$Biokin's BL-M12D1 Wins NMPA Clinical Trial Approval – ADC Candidate to Be Evaluated as Monotherapy in Relapsed or Refractory Hematologic Malignancies$

Biokin’s BL-M12D1 Wins NMPA Clinical Trial Approval – ADC Candidate to Be Evaluated as Monotherapy in Relapsed or Refractory Hematologic Malignancies

September 28, 2026

Haisco’s HSK42360-Na Granted NMPA Breakthrough Therapy Designation – BRAF Paradoxical Breaker Targets High‑Grade Glioma with BRAF V600 Mutation

September 28, 2026

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.

Explore Now

Company Deals

Mindray Bio-Medical Electronics

Biokin Scores Triple NMPA Breakthrough Therapy Designation – BL-M07D1, BL-M05D1, and Iza‑Bren Recognized Across Biliary Tract and Gastric Cancers

Biokin’s BL-M12D1 Wins NMPA Clinical Trial Approval – ADC Candidate to Be Evaluated as Monotherapy in Relapsed or Refractory Hematologic Malignancies

Haisco’s HSK42360-Na Granted NMPA Breakthrough Therapy Designation – BRAF Paradoxical Breaker Targets High‑Grade Glioma with BRAF V600 Mutation

Empowering Chinese Pharma’s Global Expansion

Mindray Bio-Medical Re-Files for Hong Kong Listing After Initial Application Expiration

Mindray Reports Mixed Q1 2026 Results with Strong International Growth Offset by Domestic Weakness

NHSA Launches 6th VBP Tender for Medical Consumables in China, Targeting Drug-Coated Balloons

Shenzhen Mindray Eyes $1 B+ Hong Kong IPO With Huatai, JPMorgan On Board

Mindray Bio-Medical Expands North American Warehouse to Enhance Operational Efficiency

NMPA Approves Shenzhen Mindray’s Innovative Dual-Mode Ultrasound Diagnostic System

Mindray Bio-Medical Partners with Nanjing Drum Tower Hospital to Boost Clinical Research

Caprico Biotechnologies and Mindray Medical Form Comprehensive Flow Testing Partnership

About Company